Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jun 7;11(21):3297-9.
doi: 10.3748/wjg.v11.i21.3297.

Pivotal molecules of MHC I pathway in human primary hepatocellular carcinoma

Wei Chen  1 , Mei-Ying Cai, Da-Peng Wei, Xia Wang
Affiliations

Pivotal molecules of MHC I pathway in human primary hepatocellular carcinoma

Wei Chen et al. World J Gastroenterol. .

Abstract

Aim: To investigate the expression of several important molecules involved in major histocompatibility complex (MHC) class I presentation pathway in primary hepatocellular carcinoma (HCC), and to determine whether cytotoxic T lymphocyte (CTL) vaccine therapy was suitable for HCC.

Methods: Labeled streptavidin biotin (LSAB) method of immunohistochemistry was used to study 33 HCC tissue specimens.

Results: Most HCC tissues and adjacent histological normal hepatocytes expressed HLA-I antigens,TAP, and B7, expression of B7 was especially strong, and there was no significant difference between them (P>0.05).

Conclusion: The MHC class I presentation pathway in primary hepatocellular carcinoma may not be abnormal or dysfunctional, and CTL could kill these tumor cells. Thus, it is suitable and practicable to design and construct CTL vaccine against HCC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expression of HLA-I antigens,TAP and B7 in HCC. A: Expression of HLA-I antigens; B: Expression of TAP; C: Expression of B7.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Melief CJ, Kast WM. Lessons from T cell responses to virus induced tumours for cancer eradication in general. Cancer Surv. 1992;13:81–99. - PubMed
    1. Ruiz-Cabello F, Garrido F. HLA and cancer: from research to clinical impact. Immunol Today. 1998;19:539–542. - PubMed
    1. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJ, Walboomers JM. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med. 1994;179:335–340. - PMC - PubMed
    1. Hosch SB, Izbicki JR, Pichlmeier U, Stoecklein N, Niendorf A, Knoefel WT, Broelsch CE, Pantel K. Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer. 1997;74:582–587. - PubMed
    1. Fan P, Wang S, Liu X, Zhen L, Wu Z. Major histocompatibility complex class II antigen and costimulatory molecule expression on the surface of breast cancer cells. Zhonghua Zhong Liu Za Zhi. 2002;24:327–330. - PubMed

Publication types

MeSH terms

Substances